EG31

EG31 is an EGFR inhibitor. EG31 effectively inhibits the proliferation of triple-negative breast cancer (TNBC) cells (GI50 values of MDA-MB-231 and Hs578T cells are 498.90 nM and 740.73 nM, respectively) and induces apoptosis by inhibiting the EGFR signaling pathway. EG31 still maintains antiproliferative activity against 5-fluorouracil (5-FU) -resistant TNBC cells (GI50: 519.5 nM) . EG31 can be used to study TNBC resistance[1].

Product Specifications

CAS Number

[360760-58-3]

UNSPSC

12352005

Target

EGFR

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

O=C1OC(C2=CC(N3C(C4=C(C3=O)C=CC=C4)=O)=CC(C5=NC6=C(C(O5)=O)C=C(C=C6)Br)=C2)=NC7=CC=C(C=C17)Br

Molecular Formula

C30H13Br2N3O6

Molecular Weight

671.25

References & Citations

[1]Otifi HM. Targeting the Inactive Conformation of the Epidermal Growth Factor Receptor Identifies EG31: A Novel Small Molecule Inhibitor Effective Against Normal and 5-Fluorouracil-Resistant Triple Negative Breast Cancer Cells. Onco Targets Ther. 2025 May 7;18:617-629.